Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
The surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine effectiveness (VE) and other preventive measures to halt the pandemic. A test-negative case–control study was conducted amo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2174779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137778674728960 |
|---|---|
| author | Paskorn Sritipsukho Thana Khawcharoenporn Boonying Siribumrungwong Pansachee Damronglerd Nuntra Suwantarat Araya Satdhabudha Chanapai Chaiyakulsil Phakatip Sinlapamongkolkul Auchara Tangsathapornpong Pornumpa Bunjoungmanee Sira Nanthapisal Chamnan Tanprasertkul Naiyana Sritipsukho Chatchai Mingmalairak Anucha Apisarnthanarak Pichaya Tantiyavarong |
| author_facet | Paskorn Sritipsukho Thana Khawcharoenporn Boonying Siribumrungwong Pansachee Damronglerd Nuntra Suwantarat Araya Satdhabudha Chanapai Chaiyakulsil Phakatip Sinlapamongkolkul Auchara Tangsathapornpong Pornumpa Bunjoungmanee Sira Nanthapisal Chamnan Tanprasertkul Naiyana Sritipsukho Chatchai Mingmalairak Anucha Apisarnthanarak Pichaya Tantiyavarong |
| author_sort | Paskorn Sritipsukho |
| collection | DOAJ |
| description | The surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine effectiveness (VE) and other preventive measures to halt the pandemic. A test-negative case–control study was conducted among adults (age ≥18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022–15 June 2022). All participants were prospectively followed up for COVID-19 development for 14 days after the enrolment. Vaccine effectiveness was estimated and adjusted for characteristics associated with COVID-19. Of the 7971 included individuals, there were 3104 cases and 4867 controls. The adjusted VE among persons receiving 2-dose, 3-dose, and 4-dose vaccine regimens for preventing infection and preventing moderate-to-critical diseases were 33%, 48%, 62% and 60%, 74%, 76%, respectively. The VE were generally higher among those receiving the last dose of vaccine within 90 days compared to those receiving the last dose more than 90 days prior to the enrolment. The highest VE were observed in individuals receiving the 4-dose regimen, CoronaVac-CoronaVac-ChAdOx1 nCoV-19-BNT162b2 for both preventing infection (65%) and preventing moderate-to-critical diseases (82%). Our study demonstrated increased VE along with an increase in number of vaccine doses received. Current vaccination programmes should focus on reducing COVID-19 severity and mandate at least one booster dose. The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine. |
| format | Article |
| id | doaj-art-4fa479761ec949b5873032835c620e5e |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-4fa479761ec949b5873032835c620e5e2025-08-20T02:30:45ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112110.1080/22221751.2023.2174779Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?Paskorn Sritipsukho0Thana Khawcharoenporn1Boonying Siribumrungwong2Pansachee Damronglerd3Nuntra Suwantarat4Araya Satdhabudha5Chanapai Chaiyakulsil6Phakatip Sinlapamongkolkul7Auchara Tangsathapornpong8Pornumpa Bunjoungmanee9Sira Nanthapisal10Chamnan Tanprasertkul11Naiyana Sritipsukho12Chatchai Mingmalairak13Anucha Apisarnthanarak14Pichaya Tantiyavarong15Center of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandCenter of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandCenter of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandDepartment of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Internal Medicine, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, ThailandDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, ThailandCenter of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandCenter of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandThammasat Postdoctoral Fellowship, Thammasat University, Pathumthani, ThailandDepartment of Surgery, Faculty of Medicine, Thammasat University, Pathumthani, ThailandCenter of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, ThailandDepartment of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathumthani, ThailandThe surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine effectiveness (VE) and other preventive measures to halt the pandemic. A test-negative case–control study was conducted among adults (age ≥18 years) who were at-risk for COVID-19 and presented for nasopharyngeal real-time polymerase chain reaction testing during the Omicron variant-dominant period in Thailand (1 January 2022–15 June 2022). All participants were prospectively followed up for COVID-19 development for 14 days after the enrolment. Vaccine effectiveness was estimated and adjusted for characteristics associated with COVID-19. Of the 7971 included individuals, there were 3104 cases and 4867 controls. The adjusted VE among persons receiving 2-dose, 3-dose, and 4-dose vaccine regimens for preventing infection and preventing moderate-to-critical diseases were 33%, 48%, 62% and 60%, 74%, 76%, respectively. The VE were generally higher among those receiving the last dose of vaccine within 90 days compared to those receiving the last dose more than 90 days prior to the enrolment. The highest VE were observed in individuals receiving the 4-dose regimen, CoronaVac-CoronaVac-ChAdOx1 nCoV-19-BNT162b2 for both preventing infection (65%) and preventing moderate-to-critical diseases (82%). Our study demonstrated increased VE along with an increase in number of vaccine doses received. Current vaccination programmes should focus on reducing COVID-19 severity and mandate at least one booster dose. The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who previously received the primary series of inactivated vaccine.https://www.tandfonline.com/doi/10.1080/22221751.2023.2174779COVID-19real-lifevaccineeffectivenessOmicron variantThailand |
| spellingShingle | Paskorn Sritipsukho Thana Khawcharoenporn Boonying Siribumrungwong Pansachee Damronglerd Nuntra Suwantarat Araya Satdhabudha Chanapai Chaiyakulsil Phakatip Sinlapamongkolkul Auchara Tangsathapornpong Pornumpa Bunjoungmanee Sira Nanthapisal Chamnan Tanprasertkul Naiyana Sritipsukho Chatchai Mingmalairak Anucha Apisarnthanarak Pichaya Tantiyavarong Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? Emerging Microbes and Infections COVID-19 real-life vaccine effectiveness Omicron variant Thailand |
| title | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? |
| title_full | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? |
| title_fullStr | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? |
| title_full_unstemmed | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? |
| title_short | Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? |
| title_sort | real life effectiveness of covid 19 vaccine during the omicron variant dominant pandemic how many booster doses do we need |
| topic | COVID-19 real-life vaccine effectiveness Omicron variant Thailand |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2023.2174779 |
| work_keys_str_mv | AT paskornsritipsukho reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT thanakhawcharoenporn reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT boonyingsiribumrungwong reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT pansacheedamronglerd reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT nuntrasuwantarat reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT arayasatdhabudha reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT chanapaichaiyakulsil reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT phakatipsinlapamongkolkul reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT aucharatangsathapornpong reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT pornumpabunjoungmanee reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT sirananthapisal reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT chamnantanprasertkul reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT naiyanasritipsukho reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT chatchaimingmalairak reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT anuchaapisarnthanarak reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed AT pichayatantiyavarong reallifeeffectivenessofcovid19vaccineduringtheomicronvariantdominantpandemichowmanyboosterdosesdoweneed |